

Personalized Literature Report

Generated 2/4/2026

Patient Summary

42

AGE

Male

SEX

Medications

valACYclovir 500 MG Oral Tablet loratadine (CLARITIN) 10 mg tablet
valACYclovir 500 MG Oral Tablet SUMatriptan succinate 25 MG Oral Tablet
ondansetron HCl 4 MG Oral Tablet rizatriptan benzoate 10 MG Oral Tablet
valACYclovir 500 MG Oral Tablet amoxicillin 875 MG Oral Tablet
levoFLOXacin 500 MG Oral Tablet Claritin +8 more

Relevant Lab Values

Cholesterol in HDL [Mass/volume] in Serum or Plasma: 55 mg/dL
Cholesterol [Mass/volume] in Serum or Plasma: 182 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 110 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma: 85 mg/dL

Study Information

Premature coronary artery disease in women: sex-specific risk factors, pathogenetic mechanisms and clinical implications

Intervention: Aggressive lipid control, metabolic risk reduction, and psychosocial support

Primary Endpoint: Early detection and tailored treatment of female PCAD

Applicability Assessment

This study may not directly apply to this patient

Based on the patient's health records, the findings from this study might not be directly applicable.

Reasons

CONDITION

Patient does not have required condition: Premature coronary artery disease

The study required patients to have Premature coronary artery disease

BIOMARKER

Missing biomarker data: lipoprotein(a)

The study results are based on lipoprotein(a) levels, which are not in the patient's records

Important: This personalized summary is based on a research study and health data. It is not medical advice. Always discuss treatment decisions with your healthcare provider. Individual results may vary from study findings.

Generated by FHIR Literature Personalization Tool